In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE
9 April, 2015
Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities
5 March, 2015
Cardiome to hold fourth quarter and full year 2014 financial results conference call on March 12
Cardiome is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems.